Shares of Guardant Health, Inc. (NASDAQ:GH – Get Free Report) have received a consensus recommendation of “Buy” from the twenty-one ratings firms that are covering the stock, Marketbeat reports. Twenty research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $53.29.
GH has been the subject of several recent research reports. Piper Sandler restated an “overweight” rating and issued a $60.00 price target (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. JPMorgan Chase & Co. increased their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group raised their target price on Guardant Health from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. UBS Group upped their price target on Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. Finally, Raymond James reissued an “outperform” rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st.
Check Out Our Latest Report on GH
Insider Transactions at Guardant Health
Institutional Trading of Guardant Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Guardant Health by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after buying an additional 350,606 shares in the last quarter. Deep Track Capital LP increased its position in Guardant Health by 7.0% in the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock valued at $196,118,000 after buying an additional 419,006 shares in the last quarter. Invesco Ltd. increased its position in Guardant Health by 100.9% in the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after buying an additional 1,403,670 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Guardant Health by 6.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after buying an additional 164,263 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after buying an additional 1,138,300 shares in the last quarter. 92.60% of the stock is owned by institutional investors.
Guardant Health Stock Down 0.7%
Shares of GH opened at $48.06 on Monday. The stock has a market cap of $5.95 billion, a PE ratio of -13.50 and a beta of 1.37. Guardant Health has a 12-month low of $20.14 and a 12-month high of $52.92. The business has a 50-day simple moving average of $42.93 and a two-hundred day simple moving average of $41.13.
Guardant Health (NASDAQ:GH – Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm’s revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. On average, equities research analysts expect that Guardant Health will post -2.9 EPS for the current year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Stories
- Five stocks we like better than Guardant Health
- Where to Find Earnings Call Transcripts
- Five Below Pops on Strong Earnings, But Rally May Stall
- How to trade using analyst ratings
- Intel’s Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
- Investing in Commodities: What Are They? How to Invest in Them
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.